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ABSTRACT
Drug-resistance to chemotherapics in aggressive neuroblastoma
(NB) is characterized by enhanced cell survival mediated by TrkB and
its ligand, brain-derived neurotrophic factor (BDNF); thus reduction in
BDNF levels represent a promising strategy to overcome drug-
resistance, but how chemotherapics regulate BDNF is unknown.
Here, cisplatin treatment in SK-N-BE neuroblastoma upregulated
multiple BDNF transcripts, except exons 5 and 8 variants. Cisplatin
increased BDNF mRNA and protein, and enhanced translation of a
firefly reporter gene flanked by BDNF 5′UTR exons 1, 2c, 4 or 6 and
3′UTR-long. To block BDNF translation we focused on aurora
kinases inhibitors which are proposed as new chemotherapeutics.
NB cell survival after 24 h treatment was 43% with cisplatin, and 22%
by cisplatin+aurora kinase inhibitor PHA-680632, while the aurora
kinases inhibitor alone was less effective; however the combined
treatment induced a paradoxical increase of BDNF in surviving cells
with strong translational activation of exon6-3′UTR-long transcript,
while translation of BDNF transcripts 1, 2C and 4 was suppressed. In
conclusion, combined cisplatin and aurora kinase inhibitor treatment
increases cell death, but induces BDNF overproduction in surviving
cells through an aurora kinase-independent mechanism.
KEY WORDS: Neuroblastoma, Drug resistance, Neurotrophins,
Cisplatin, Aurora kinase, PHA-680632
INTRODUCTION
Neuroblastoma (NB) is a solid tumour derived from the sympatho-
adrenal lineage of the neural crest cells and is the most common
paediatric tumour accounting for 15% of cancer-related death in
children (Nakamura et al., 2014). NBs can have either a favourable
or an unfavourable prognosis depending on intrinsic features
including the expression of neurotrophic factors of the
neurotrophin family and their receptors, which are involved in cell
survival and differentiation during development (Skaper, 2012;
Brodeur et al., 2009). In particular, favourable NBs express TrkA
(the receptor for nerve-growth factor) while unfavourable NBs
express TrkB and its ligand, brain-derived neurotrophic factor
(BDNF), and amplification of the oncogene MYCN (Brodeur et al.,
2009; Buhagiar and Ayers, 2015). There is consolidated evidence
that increased expression of BDNF and its receptor TrkB, working
in an autocrine/paracrine way, is able to confer resistance to
chemotherapeutics, leading NBs to display enhanced cell survival
and aggressiveness (Nakamura et al., 2014; Nakagawara et al.,
1993). Indeed, overexpression of TrkB blocks drug-induced cell
death in a dose-dependent manner (Jaboin et al., 2002). Similar
effects can also be obtained by BDNF treatment, while drug
susceptibility can be restored after TrkB inhibition using K252a
(Jaboin et al., 2003, 2002) or blocking BDNF availability using
anti-BDNF neutralizing antibodies (Ho et al., 2002; Feng et al.,
2001). The mechanism of BDNF pathway-mediated resistance to
the most commonly used anti-tumour drugs in NB (cisplatin,
vinblastine, etoposide and doxorubicin) has been described. BDNF/
TrkB contributes to drug resistance and cell survival by increasing
phosphorylation of AKT via the phosphatidylinositol 3′-kinase
(PI3K)/AKT pathway (Ho et al., 2002), and the inhibition of PI3K
restores cisplatin-induced cytotoxicity (Jaboin et al., 2003).
BDNF is a secreted, small dimeric protein which is produced
from a large number of transcripts generated by alternative splicing
of eight upstream exons encoding the 5′ untranslated region (UTR),
and a common downstream exon 9 containing a unique coding
region and a short or long 3′UTR region (Fig. 1A) (Aid et al., 2007;
Pruunsild et al., 2007). In a previous study, using siRNAs targeted
to each individual BDNF transcripts, we demonstrated that siRNAs
against either the coding sequence (exon 9) or the isoforms 4, 6, 9a
that are located in the second exon cluster were able to decrease the
survival of SK-N-BE neuroblastoma cells (a model carryingMYCN
amplification) following treatment with cisplatin (Baj and
Tongiorgi, 2009). These results suggested that BDNF transcript-
specific silencing could aid in increasing the efficacy of treatments
for drug-resistant NBs.
Inhibitors of aurora kinases have recently been proposed as a novel
class of antitumoral chemotherapeutics to target drug-resistant NBs
(Maris, 2009; Michaelis et al., 2014). The aurora kinase family
comprises three serine/threonine kinases (AURKA, AURKB, and
AURKC) involved in centrosome function and spindle organization
during mitosis, and in the regulation of the cell cycle (Fu et al., 2007).
These kinases have gained interest as drug targets since they act as
oncogenic drivers in many human cancers (Maris, 2009). Aurora
kinases expression and amplification, especially AURKA, are
negative prognostic markers indicating high-risk disease in drug-
resistant neuroblastoma cells (Michaelis et al., 2014). In addition,
AURKA stabilizes N-Myc protein which is normally degraded
following low levels of PI3K activity, thus promoting mitosis exit
(Otto et al., 2009). Aurora kinases also regulate translation through the
phosphorylation of cytoplasmic polyadenylation element binding
protein (CPEB), which binds to cytoplasmic polyadenylation element
(CPE) onmRNA transcripts (Groisman et al., 2006; Otto et al., 2009).
Importantly, this is a conserved mechanism being described from
Xenopus oocytes to human neurons where, in addition to translational
regulation, it is also involved in dendritic mRNA trafficking (Huang
et al., 2002). It is noteworthy that all BDNF transcripts include a CPEReceived 31 December 2015; Accepted 12 May 2016
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element in the 3′UTR (Oe and Yoneda, 2010; Vicario et al., 2015). In
this study, we tested the hypothesis that cisplatin might induce drug
resistance in one aggressive MYCN-amplified neuroblastoma by
affecting the regulation of endogenous BDNF levels. Secondly, we
attempted to increase cell mortality by combining cisplatin with the
aurora kinase inhibitor PHA-680632, which we used to prevent
BDNF translation. Finally,we evaluated theBDNFproteinproduction
in the neuroblastoma cells which survived the combined treatment.
RESULTS
Cisplatin treatment increases BDNF in differentiated SK-N-
BE neuroblastoma cells
We previously demonstrated that SK-N-BE neuroblastoma cells
differentiated with 9-cis retinoic acid show higher production of
BDNF and its receptor, TrkB. Differentiated cells resulted to be
more resistant to cisplatin-induced death with respect to
undifferentiated cells, and silencing of BDNF attenuated this
effect (Baj and Tongiorgi, 2009). Given these observations, we
investigated whether cisplatin is able to modulate BDNF
expression. SK-N-BE cells were differentiated for 4.5 days with
9-cis retinoic acid followed by cisplatin treatment (5 µg/ml) in
serum-free medium for 1, 3, 6, 12 and 24 h. After RNA extraction
and retro-transcription, total BDNFmRNAwas quantified through
real time PCR (N=3 independent cultures). We found a significant
increase (2.5-fold, ***P<0.001) in BDNF coding sequence
mRNA expression after 6 h, which was stable up to 12 h and
was more pronounced (8.6-fold, ***P<0.001) after 24 h of
treatment (Fig. 1B). BDNF has a complex gene structure (see
Fig. 1A) characterised by different 5′-untranslated regions (UTR),
each encoded by a different exon spliced to a common downstream
exon containing the coding sequence (CDS) and the 3′UTR that
exists in two forms, one short and one long, due to the presence of
two polyadenylation sites. The different BDNF splice variants are
transcribed independently, and in humans give rise to a total of 34
possible transcripts (Pruunsild et al., 2007, 2011; Aid et al., 2007).
We found that the increase in BDNF expression induced by
cisplatin was not limited to the coding sequence but involved
almost all transcript variants (1, 2, 3, 4, 6, 7 and 9a), especially
after 24 h of treatment. Exons 5 and 8 variants were only slightly
increased, although not significantly. Expression of exons 3, 6 and
7 was increased already after 6 h of cisplatin treatment, while we
observed a transient decrease in exon 4 expression at this time
point (Fig. 1C).
We then verified if the increased expression of BDNF transcripts
corresponded to a change in BDNF protein production upon the
same treatments. Using a sandwich ELISA normalized by loading
the same total protein amount, we observed a slight but significant
decrease in BDNF protein levels at 1 h of cisplatin treatment and a
return to control levels after 12 h. Treatment for 24 h enhanced
BDNF protein levels by around 20% above the basal level (untreated
control; ***P<0.001, one-way ANOVA; see Fig. 2A). Similar
results were obtained also by western blot using a semi-quantitative
densitometric analysis of the mature BDNF band signals
normalized to tubulin bands. Indeed, there was no significant
variation in mature BDNF levels after 6 h, but 24 h of treatment
induced about 30% increase in mature BDNF protein (**P=0.007,
one-way ANOVA; Fig. 2B).
Since the different BDNF transcripts are upregulated by cisplatin
treatment, we investigated which of them is more efficiently
translated, hence contributing mostly to BDNF protein production.
In a previous study from our laboratory, we developed an in vitro
translation assay by which we demonstrated that different BDNF
Fig. 1. Increment in BDNF transcripts after cisplatin
treatment. (A) BDNF human gene structure according
to Pruunsild et al. (2007). We represented only
isoforms that were relevant for this study. (B) Total
BDNFCDS expression in SK-N-BE cells (differentiated
4.5 DIV) and treated in serum free medium (SFM)
+Cisplatin (5 µg/ml). RNAs were extracted at different
time points after cisplatin treatment: 0 (untreated
control), 1, 3, 6, 12, 24 (N=3). (C) Modulation of single
BDNF mRNA isoforms (exons are given in the x-axis)
at 6 and 24 h of cisplatin treatment, normalized to the
untreated control (0) (N≥4). B and C data were
collected through real time PCR with SYBR® Green
Technology and data are given as mean±s.e.m.
(*P<0.05, **P<0.01, ***P<0.001; one-way ANOVA).
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transcripts display a different efficiency of translation, basally and
after stimulation, and this ability is influenced by the presence
of both 5′ and 3′UTRs (Vaghi et al., 2014). Accordingly, we
transfected SK-N-BE cells with a construct holding a firefly
luciferase (Fluc) reporter gene flanked by different 5′UTR (exons 1,
2c, 4 and 6, alternatively) and the 3′UTR long. Exons 1, 2, 4 and
6 are the most abundant BDNF transcripts accounting together
for 96% BDNF mRNA in the brain (Baj et al., 2013). In order
to normalize for differences in transfection efficiency we
co-transfected the same cells with a control vector bearing a
second reporter, namely Renilla luciferase (Rluc). After treatments,
Fluc bioluminescence activity was recorded and double-normalized
over the Rluc activity and the untreated condition within the same
experiment. After 24 h of cisplatin treatment, we observed that
exons 1, 2c, 4 transcripts showed a significant increase in translation
(**P<0.010; Fig. 2C); while exon 6 translation although
significantly increased (*P=0.020) displayed a high variability,
possibly due to the fact that exon 6 is translationally repressed in
basal conditions. Of note, the 3′UTR long alone does not
substantially contribute to the efficiency of translation of BDNF
following cisplatin treatment, in analogy with other drugs tested in a
previous study (Vaghi et al., 2014). These results indicate that the
production of BDNF is increased in the subpopulation of surviving
cells.
An aurora kinases inhibitor enhances the cisplatin cytotoxic
effect
We hypothesized that by reducing aurora kinase A activity we
may enhance the cytotoxic effect of cisplatin by overcoming the
increased production of BDNF in surviving neuroblastoma cells,
as a consequence of reduced aurora kinase-dependent BDNF
translation. To test this hypothesis, we treated SK-N-BE cells
with the aurora kinases inhibitor, PHA-680632 (Soncini et al.,
2006), either alone (10 µM) or in combination with cisplatin
(5 µg/ml) in serum-free medium for 1, 3, 6, 12 and 24 h. Using a
MTT viability assay we found that the aurora kinases inhibitor
alone was poorly effective in reducing cell survival with respect
to control conditions (i.e. cells treated with vehicle DMSO, set
to=100% survival at time zero). Treatment with cisplatin alone
caused about 43% survival by 24 h (*P<0.05, two-way
ANOVA), while the combined treatment with cisplatin and the
aurora kinases inhibitor caused a dramatic reduction in cell
viability at all time points tested, starting from 3 h of treatment
and reaching 22% of viability after 24 h (Fig. 3A) (*P<0.050,
***P<0.001, two-way ANOVA versus control; #P=0.012, one-
way ANOVA versus aurora kinases inhibitor alone). In
conclusion, a statistically significant decrease in cell viability
was present at all tested time points, but at 24 h the reduction
was particularly relevant (Fig. 3A). These results also show that
there is not a synergic effect of cisplatin+aurora kinase inhibitor,
PHA-680632. Fig. 3B shows the effectiveness of aurora
kinase inhibitor in reducing aurora A phosphorylation, which
was significantly decreased after 6 h of treatment (*P=0.010,
P=0.006 after 24 h, one-way ANOVA versus untreated control),
while PHA-680632 had no effect on total aurora A kinase
protein levels. Overexpression of aurora kinase A induced only a
slight increase in its phosphorylation which was not
significantly affected by 6 and 24 h cisplatin. The effects of
cisplatin alone or cisplatin+PHA-680632 combined treatment at
6 and 24 h were also measured by counting the number of cells,
identified through Hoechst staining for cell nuclei and actin for
cytoplasm. This quantitative assessment of cell number was
achieved with a stereological unbiased procedure carried out in
three different fields randomly positioned in each well of 24-
wells plates (N=3 cultures) in the different treatment conditions
(Fig. 3C,D). A significant reduction in cell number with respect
to the untreated control, which was set as=100%, was observed
after 24 h of combined treatment with cisplatin and aurora kinase
inhibitor (**P=0.003; one-way ANOVA; Fig. 3D), thus
providing a further corroboration of the results obtained with
the MTT assay.
Fig. 2. Cisplatin increases both BDNF protein production and mRNA
translational efficiency. (A) ELISA detection of total BDNF protein level in 4.5
DIV differentiated SK-N-BE cells after cisplatin treatment, at different time
points: untreated control (0), 1, 3, 6, 12 and 24 h (N=4, each in duplicate).
(B) Evaluation of mature BDNF protein production through densitometric
analysis of western blot, in the same conditions as described in panel A, but
limited to time point treatment of 6 and 24 h; BDNF signal is normalized to
tubulin and given as percentage of variation with respect to control. Lower
panel: representative western blot of mature BDNF and tubulin (N=3).
(C) Translational efficiency of different BDNF isoforms under cisplatin cytotoxic
stress, at 6 and 24 h time points. The isoforms tested are as follows: exon1-
Fluc-3′UTR long (Ex1-F-3′L), exon2c-Fluc-3′UTR long (Ex2c-F-3′L), exon4-
Fluc-3′UTR long (Ex4-F-3′L) and exon6-Fluc-3′UTR long (Ex6-F-3′L). Values
from each isoform are normalized for transfection efficiency over a control
vector (Rluc) and given as fold increase on basal condition (0); N=3, each in
duplicate; RLU: relative luciferase unit. In all panels, data are represented as
mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA versus
untreated control.
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Effects of aurora kinases inhibition on BDNF protein
production
Assuming that inhibition of aurora kinases would cause a decrease
in BDNF protein levels, we verified the effective inhibition of
BDNF protein expression using an anti-BDNF specific monoclonal
antibody to visualize the protein by immunofluorescence, and an
anti-actin antibody to visualize cell boundaries. BDNF protein was
clearly detected as bright fluorescent spots inside neuroblastoma
cells (Fig. 4A, BDNF in green, actin in red). Of note, to generate
this figure and for better visual comparison, small fields containing
a similar number of cells were selected, while the general
appearance of the cultures is shown in Fig. 3 and assessment of
spot number was achieved with a stereological unbiased procedure
carried out in five different fields randomly positioned in each well.
In the last row of Fig. 4A, cell boundaries identified on the basis of
actin staining are outlined in red and BDNF spots are reported as
black dots on a white background, this representation was used to
count spots. The count of individual spots normalized for cell area,
defined on the basis of actin staining, is shown in Fig. 4B expressed
as number of spots per micron square (spots µm−2). In particular,
under basal conditions we counted a density of 0.21±0.04 BDNF
spots µm−2 (mean±s.e.m.) which remained unchanged after 6 h of
treatment either with cisplatin alone or combined to PHA-680632,
rising to 0.31±0.03 BDNF spots µm−2 after 24 h of treatment with
cisplatin alone (P=0.039, one-way ANOVA) and up to 0.40±0.02
after treatment with both cisplatin and the aurora kinase inhibitor
(P=0.004, one-way ANOVA). Notably, the mean BDNF spot area
did not change upon treatments with respect to untreated control
(Fig. 4C). In conclusion, this analysis revealed a clear enrichment
of BDNF spots in surviving neuroblastoma cells after 24 h of
combined treatment with cisplatin and PHA-680632. Thus, the
22% of neuroblastoma cells remaining in the culture after the
combined cisplatin+PHA-680632 treatment showed a paradoxical
increase in BDNF.
To investigate the contribution of individual transcripts to
BDNF increase we used the luciferase translation assay and found
that while the cisplatin-dependent increase in translation from
exons 1, 2c and 4 was completely suppressed at both 6 and 24 h
by combined treatment with PHA-680632, translation from exon 6
showed a strong increase of about sixfold at 24 h (but not 6 h)
of treatment (***P<0.001, one-way ANOVA; see Fig. 4D); again,
the 3′UTR long sequence alone did not affect translation
under cisplatin+PHA-680632 treatment. SYBR-green qRT-PCR
experiments showed that cisplatin treatment alone or in
Fig. 3. Combined treatment of cisplatin and PHA-680632 enhances cell mortality. (A) Residual viability in SK-N-BE cells treated for different hours with
cisplatin and/or PHA-680632 (aurora kinase inhibitor). All treatment were performed after 4.5 DIV of differentiation and quantified through colorimetric MTT assay.
DMSO treatment represents the control group. Data are given as mean±s.e.m. of percentage viability (N=3, each in triplicate). Statistical differences were
assessed performing a two-way ANOVA and Bonferroni correction versus control. *P<0.05, ***P<0.001, #P=0.012, one-way ANOVA versus aurora kinases
inhibitor alone. (B) Densitometric quantification of phospho-aurora in SK-N-BE cells, double normalized on total aurora A protein of each culture, and related to
untreated cultures with either normal levels (=100%) or with overexpressed aurora A kinase (=100%). Cells were treated for 6 or 24 h with cisplatin alone or in
combination with PHA-680632 inhibitor. Upper panel: representative western blot with tubulin as loading control; lower panel: densitometric analysis from 3
independent experiments. Data are given as percentage mean±s.e.m. *P=0.01, **P=0.006; one-way ANOVAversus untreated control. (C) Immunofluorescence
onSK-N-BE cells treated for 6 or 24 h with cisplatin alone or in combination with PHA-680632 inhibitor. Hoechst was used to highlight nuclei and actin wasmarked
to emphasize cell bodies; the merge between the two channels is displayed. (N=3; scale bar: 20 µm). (D) Cell count from the immunofluorescence described in
panel B. Values are given asmean±s.e.m. of percentage of cell number with respect basal condition (N=3). **P=0.003; one-way ANOVAversus untreated control.
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combination with PHA-680632 did not significantly affect the
levels of firefly luciferase mRNA expressed by the four constructs
and normalized by the mRNA levels of Renilla luciferase used as
transfection control (Fig. 4E). The experiments described above
demonstrated that cisplatin-induced translation of BDNF exons 1,
2c and 4 requires active aurora kinase, however, the paradoxical
increase of BDNF exon 6 translation poses the question if aurora
kinase in also involved in regulating this transcript or not. Hence,
we tested the role of aurora kinase when BDNF translation is
induced with a non-cytotoxic stimulus, consisting in a general
mild depolarization obtained with high potassium solution
(20 mM KCl). Neuroblastoma cells were treated for 3 h with
KCl 20 mM alone or in the presence of PHA-680632 aurora-
kinases inhibitor, or 50 nM GF 109203X a selective inhibitor of
protein kinase C (PKC) which does not regulate BDNF translation
in neuroblastoma cells (Heikkila et al., 1993). High KCl induced
an almost 300% increase in exon-6-3′UTR long luciferase activity
(**P=0.006, one-way ANOVA) which was not affected by the GF
109203X (PKC-inhibitor; *P=0.011, one-way ANOVA) and was
completely abolished by PHA-680632 aurora-kinases inhibitor
(P=0.796 one-way ANOVA; Fig. 4F). Taken together, these
results demonstrate that, in response to a physiological stimulus
consisting in cell depolarization, BDNF exon 6-containing
transcripts are translated using a mechanism which requires
aurora kinase, but in the presence of a cytotoxic stimulus,
translation of these transcripts is driven by an aurora kinase-
independent mechanism.
DISCUSSION
In this study we found that cisplatin-induced cytotoxic stress was
able to stimulate BDNF production in the MYCN-amplified
neuroblastoma cell line SK-N-BE by enhancing both transcription
and translation of multiple BDNF mRNAs. We further showed that
the combined treatment with cisplatin and the aurora kinases
inhibitor PHA-680632 was very effective in reducing cell survival
from 43% with cisplatin alone to 22% with the combined treatment.
At the same time we observed a paradoxical increase in BDNF
production that was accounted for by a strong translational
activation of transcripts bearing exon 6 and the 3′UTR long,
while translation of BDNF transcripts 1, 2C and 4 was suppressed
Fig. 4. Increment in BDNF protein production and exon-6 translation upon combined treatment of cisplatin and PHA-680632. (A) Immunofluorescence
on SK-N-BE cells treated with cisplatin±PHA-680632 (aurora inhibitor) at different time points: untreated control (0), 6 and 24 h. BDNF spots are detected using a
mouse mAb and actin is marked using a rabbit pAb to emphasize cell bodies; the merge of the two channels is shown as well as its outline, where black dots
represent the BDNF spots and red lines the edges of the cell bodies (N=3; scale bar: 10 µm). (B) BDNF spot number analysis from the immunofluorescence
described in panel C. Data are given as number of spots per µm2. N=3; *P=0.039, **P=0.004; one-way ANOVA versus untreated) (C) BDNF spot area
analysis, normalized to untreated control. (D) Translational capacity of different BDNF isoforms in differentiated SK-N-BE treated as described in panel A. The
isoforms tested and the normalization procedures are the same as described in Fig. 2, panel C. RLU, relative luciferase unit. N=3, each in duplicate. ***P<0.001;
one-way ANOVA untreated control). (E) Quantitative real-time PCR to evaluate the effects of treatment, for 24 h with cisplatin±PHA-680632, on the expression of
firefly luciferase (Fluc) mRNA, normalized to the expression of theRenilla luciferase used as transfection control (N=2). (F) Effect on exon 6-Fluc-3′Long efficiency
of translation after 20 mMKCl treatment for 3 h, alone or in combination with GF 109203X (PKC inhibitor) or PHA-680632 (aurora inhibitor) for 30 min of treatment.
N≥3; *P=0.03, **P=0.006; one-way ANOVA versus control). For all panels, data are given as mean±s.e.m.
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by the combined treatment. Taken together, these results suggest
that drug-resistance and cell survival in cisplatin-treated
neuroblastoma cells could be mediated by increased BDNF
production in response to cytotoxic stress, in particular through
enhanced translation of exon-6 with an aurora kinase-independent
mechanism.
BDNF is generated as a unique protein precursor encoded by a
single coding sequence (CDS), but its gene regulation is highly
complex because of the presence of multiple untranslated regions
which are alternatively spliced to give rise, in humans, to 34
transcripts, each of which is independently transcribed (Aid et al.,
2007; Pruunsild et al., 2007, 2011). It has previously been
demonstrated that different BDNF mRNA variants target different
cell compartments, especially in neurons, in an activity-dependent
manner (Tongiorgi et al., 1997); for example, exons 1, 3, 5, 7, 8 and
9a preferentially segregate to soma, exon 4 to proximal dendrites
while exons 2 and 6 reach the distal dendrites (Baj et al., 2013,
2011). In addition, they display different ability to be translated in
response to various compounds (Vaghi et al., 2014). Concerning the
role of BDNF in neuroblastoma tumours, previous studies
suggested that BDNF and its receptor TrkB are involved in an
autocrine loop that promotes cell survival and resistance to
chemotherapy (Baj and Tongiorgi, 2009; Jaboin et al., 2002).
Here we demonstrate that 24 h of cisplatin treatment and serum
deprivation are able to increase both total BDNF protein and the
transcripts encoding all 5′UTR variants, with the exception of exons
5 and 8. Notably, changes in BDNF protein levels do not match
mRNA levels, a well-established phenomenon that has been
previously described also in normal brain (Tropea et al., 2001). In
addition, in this study we show that cisplatin boosted translation of a
firefly reporter gene flanked by 5′ and 3′UTRs of BDNF transcript
(i.e. the 5′UTR exons 1, 2c, 4 or 6 and the 3′UTR long sequence),
highlighting the involvement of mechanisms that control the
induction of BDNF translation. These findings provide an
explanation to previous observations from our lab in which
silencing of exons 4 and 6 resulted in a significant reduction in
SK-N-BE viability under cisplatin treatment (Baj and Tongiorgi,
2009). In conclusion, one of the major findings of the present study
is that cisplatin induces upregulation of BDNF at both
transcriptional and translation level.
How can cytotoxic conditions induced by cisplatin promote
BDNF translation? Cisplatin [cis-diamminedichloro platinum(II)] is
a metal compound commonly used in clinic as an antitumor drug
that induces cell damage mainly by cross-linking genomic DNA
and, to a lesser extent, proteins. DNA damage triggers different
phenomena: on one hand, it causes cell death by necrosis (mainly by
PARP-induced ATP depletion) (Fuertes et al., 2003) and/or
apoptosis both via intrinsic and extrinsic programmed cell death
pathways, leading to final activation of caspase-3-6-7 (Zhou et al.,
2002). On the other hand, DNA damage promotes cell cycle arrest,
DNA repairing mechanisms and activation of cell survival
pathways. These cisplatin-induced pathways require functional
activity of transduction mediators, like Akt, ERK and mTOR, which
are known also to control protein translation (Cepeda et al., 2007;
Cunha et al., 2010). It has previously been shown that BDNF
resistance to cisplatin specifically involves rescue from cell-death
by TrkB-mediated activation of the PI3K/Akt pathway (Jaboin
et al., 2003). Interestingly, BDNF/TrkB signaling was shown to
facilitate local translation at synapses by activation of mTOR via
PI3K, and both mTOR and ERK are able to regulate the assembly of
the elF4E complex, contributing to translation induction (Schratt
et al., 2004). These previous findings support the view that cisplatin
may directly activate the pathways which control 5′cap-dependent
BDNF translation.
Aurora kinase/CPEB is another pathway which is implicated in
translation. This mechanism was previously described for CPE-
containing α-Ca2+/calmodulin-dependent protein kinase II
(αCaMKII) mRNA and is highly conserved among vertebrates
(Huang et al., 2002). Briefly, upon binding of CPEB and other
proteins to the cap-binding subunit (elF4E), mRNAs are kept
translationally dormant and are characterized by short poly(A) tails.
The phosphorylation of CPEB by aurora kinase stimulates mRNA
polyadenilation and the release of elF4E, which is then free to bind
and recruit the 40S ribosomal subunit and start scanning the mRNA
for the translation initiation (Huang et al., 2002; Pestova et al., 1998).
Considering that BDNF transcripts bear the CPE element in their 3′
UTR,we hypothesised that BDNF translation could use a mechanism
similar to that mediated by aurora kinase for αCaMK II mRNAs.
Therefore, by blocking aurora kinase activity with the PHA-680632
inhibitor (Soncini et al., 2006), we were expecting increased cell
mortality due to a dual effect: altered cell cycle control and decreased
BDNF protein translation. While we found that translation of exon 1,
2c and 4 was indeed blocked by the inhibition of aurora kinase, thus
confirming the role of this kinase in BDNF translation, exon 6
escaped this blockade. However, when BDNF translation was
induced by a non-cytotoxic, physiological stimulus such as
membrane depolarization, we found that also exon 6 translation
was driven by an aurora kinase-dependent mechanism. Of note, even
if the combination of PHA-680632 and cisplatin enhanced exon 6
translation, we observed an increased cell death suggesting a
potentially additive chemotherapeutic effect. It was previously
shown that cisplatin promotes cell death though activation of an
apoptotic pathway in several types of tumours (Bottone et al., 2008).
Our study did not investigate if enhanced cell death following
combined treatment with cistplatin and PHA-680632 also occurs
through apoptosis, and therefore future investigations are required.
It is noteworthy that BDNF exon 6 transcript has been reported to
be translationally repressed under resting conditions, pointing out a
tight regulation of translation for this BDNF variant (Vaghi et al.,
2014; Baj and Tongiorgi, 2009). Interestingly, it has previously
been hypothesized that transcripts bearing exon 6 may contain an
internal ribosome entry sites (IRES) sequence which may be
activated when 5′ cap-dependent translational mechanisms are
repressed (Zaitsev and Lu, 2003). Thus, this BDNF transcript which
represents also the main transcript present in distal dendrites (Baj
et al., 2013) may provide the template for a rapid and massive
production of BDNF in conditions of cellular stress able to block 5′
cap-mediated translation (Pinkstaff et al., 2001). It is conceivable
that while translation of all other BDNF transcripts is efficiently
suppressed by the combination of cisplatin and aurora kinase
inhibitor, the presence of a putative IRES within the exon 6 may
allow this transcript to escape from repression of canonical 5′CAP-
dependent translation; however demonstration that an IRES-like
mechanism is at the basis of the paradoxical increased translation of
BDNF exon-6 goes beyond the scope of this study, and therefore
further researches are warranted. One further limitation of this study
is that while cisplatin behaviour in cultured neuroblastoma cells was
shown to be similar to that in vivo (Bassili et al., 2010), the
combined effects with the aurora kinases inhibitor PHA-680632
should be replicated also in vivo, which is a matter for future
investigations. Moreover, although the SK-N-BE cell line is a well-
accepted model of MYCN-amplified aggressive neuroblastoma,
experiments on additional cell lines may further validate our
findings
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In conclusion, the observations made could have important future
implications in the use of cisplatin and Aurora kinase inhibitors
in combination for the neuroblastoma treatment. Although their
combined use show increased activity in the induction of
neuroblastoma cell death, specific attention should be paid to the
possibility that they could lead to the selection of resistant cells
expressing high BDNF levels.
MATERIALS AND METHODS
Cell cultures and reagents
Human neuroblastoma cell lines SK-N-BE were grown and differentiated as
previously described (Baj and Tongiorgi, 2009). Briefly, cells were cultured
in Dulbecco’s Modified Eagle’s Medium (DMEM) with stable L-Glutamine,
100 U ml−1 penicillin, 100 µg/ml streptomycin and 10% decomplemented
fetal bovine serum (FBS) (all purchased from EuroClone, Milan, Italy) at
37°C with 5% CO2. Differentiation was induced 24 h after plating by adding
5 µM of 9-cis retinoic acid (R4643, Sigma-Aldrich) to cultures and replaced
after 48 h. Differentiated cells (4.5 days) were treated with 5 µgml−1 cisplatin
with or without 10 µM of the Aurora kinases inhibitor PHA-680632 (both
drugswere a gift fromP. Carpinelli, NervianoMedical Sciences) in serum free
medium (SFM). GF 109203X (PKC-inhibitor) was purchased from Sigma-
Aldrich (B6292) and used at 50 nM (Heikkila et al., 1993).
Real-time PCRs
For quantification of BDNF cds and isoforms, total RNAwas extracted, using
TriZol® Reagent (15596026, Invitrogen by Thermo Fisher Scientific,
Waltham, MA, USA), from differentiated SK-N-BE cells after different
hours of cisplatin treatment: 1, 3, 6, 12 and 24 h and a non-treated control. One
microgram of total RNA was reverse-transcribed into cDNA as previously
described (Baj and Tongiorgi, 2009) and employed for a quantitative real time
PCR (qRT-PCR), performed using the RotorGene 6000 instrument according
to the manufacturer’s instructions. The PCR reactions were carried out in a
final volume of 20 µl with 2× Fluocycle II, Master SYBR Green Mix
(ERD001250, EuroClone, Milan, Italy), 0.5 µM of each primer and 1 µl of
cDNAwas added as template. The qRT-PCR was used to evaluate both total
and BDNF splice variants expression after cisplatin treatment at the given time
points. For quantification of firefly (Fluc) and Renilla (Rluc) luciferases
mRNA, differentiated SK-N-BE cells were transfected with plasmid vectors
as described later in the ‘Luciferase assay’ paragraph. After treatment for 24 h
with cisplatin±PHA-680632 inhibitor, total RNA was extracted as described
above, treated with DNase I (18068015, Invitrogen by Thermo Fisher
Scientific) then 1 µgwas reverse-transcribed using SuperScript III (18080044,
Invitrogen byThermoFisher Scientific). The qRT-PCR reactionswere carried
out in a final volume of 12 µl with 2× PowerUp™ SYBR® GreenMaster Mix
(A25741, Applied Biosystem, by Thermo Fisher Scientific), 0.2 µM of each
primer and 1/20 µl of cDNAwas added as template. Rluc expressionwas used
as transfection control. All primer pairs used along with the PCR conditions
are listed in Table 1.
ELISA assay for total BDNF detection
BDNF levels in differentiated SK-N-BE cells were assessed using the
ELISA BDNF Emax Immunoassay System (G7610, Promega Corporation,
Madison, WI, USA) at the same time points evaluated in real-time PCR.
Briefly, cells in treated and control conditions were lysed and 12.5 µg of
total protein were loaded on pre-coated wells according to manufacturer’s
instructions.
Western blotting
Differentiated SK-N-BE cells were lysed on ice in lysis RIPA buffer
[50 mM Tris-HCl pH 8.0, EDTA 1 mM, 150 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail (P8849,
Sigma-Aldrich)]. Protein quantification was performed via Bradford assay
(ab119216, Abcam, Cambridge, UK), according to manufacturer
instructions. Proteins were resolved into 15% SDS-PAGE, loading equal
amount of total protein (20 µg) and electroblotted onto nitrocellulose
membrane. Membranes were cut above the 35 KDa marker band and
differentially processed. The lower portion of the membrane was blocked
with fat-free 10% milk in PBS-T [Phosphate Buffer Saline, 0.1% (v/v)
Tween-20] and then incubated at 4°C in overnight gentle-shaking with anti-
BDNF N-20 antibody (1:500 in blocking solution; sc-546, Santa Cruz,
Texas, USA). After three wash steps with PBS-T, the membranes were
incubated for 1 h at room temperature with anti-rabbit HRP-conjugated
antibody (1:10,000 in fat-free 5% milk in PBS-T; A0545 Sigma-Aldrich).
The upper part of the membrane was blocked with fat-free 5% milk in
PBS-T, then incubated overnight at 4°C alternatively with the following
antibodies: anti-phospho Aurora kinases (1:1000, polyclonal; 2914S, Cell
Signaling Technology, MA, USA), anti-aurora kinase A (1:1000,
polyclonal; 3092S, Cell Signaling Technology), or with anti-αTubulin
antibody (1:8000, monoclonal; T6074, Sigma-Aldrich). After threewashing
steps, a further incubation for 1 h at room temperature was performed with
secondary HRP-conjugated antibodies, specifically anti-rabbit against
primary polyclonal antibodies (1:10,000 in fat-free 5% milk in PBS-T), or
anti-mouse for monoclonal antibody (1:10,000 in fat-free 5% milk in
PBS-T; RABHRP1, Sigma-Aldrich). Thereafter, all the membranes were
washed three times and developed with ECL Prime (GE Healthcare,
Buckinghamshire, UK) on X-ray film (AU1102, Aurogene S.R.L., Rome,
Italy). Densitometric analyses of the western blots were performed using
Quantity One software (Bio-Rad Laboratories, CA, USA), according to user
manual.
Table 1. Real-time PCR primers, product size and PCR conditions used for real-time PCR experiments
Primers Sequence Product size (nt) qRT-PCR conditions
Ex. 1 fwd CTTCCAGCATCTGTTGGGGAGACG 205 45× (95°C 20″, 56°C 20″, 72°C 45″)
Ex. 2 fwd CCAGCGGATTTGTCCGAGGTGG 192-404-487
Ex. 3 fwd AGCCCAGTTCCACCAGGTGAG 165
Ex. 4 fwd ACCGAAGTCTTCCCCAGAGCAG 219
Ex. 5 fwd ACCAATAGCCCCCATGCTCTG 227
Ex. 6 fwd TGGAGCCAGAATCGGAACCAC 209-227
Ex. 7 fwd CCACATCTCTACCCATCCTGC 305
Ex. 8 fwd TGGCATGACTGTGCATCCCAG 253
Ex. 9a fwd ACAATCAGATGGGCCACATG 238
Common rev ACGCTCTCCAGAGTCCCATG –
CDS fwd AAACATCCGAGGACAAGGTGGC 230
CDS rev GGCACTTGACTACTGAGCATCACC
GAPDH fwd GGTGAAGGTCGGAGTCAACGGA 240
GAPDH rev GAGGGATCTCGCTCCTGGAAGA
Fluc fwd AGGTGGCTCCCGCTGAAT 137 50°C 2′, 95°C 2′, 40× (95°C 5″, 60°C 30″)
Fluc rew CATCGTCTTTCCGTGCTCC
Rluc fwd GCCATGATTGGGGTGCTTGT 121
Rluc rev TCAGGCCATTCATCCCATGA
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Luciferase assay
Luciferase assays, to evaluate the translational capacity of BDNF isoforms,
were performed as described previously (Vaghi et al., 2014). Briefly,
plasmid vectors containing 5′ UTR exons 1, 2c, 4 or 6 and 3′URT long
cloned at the edges of a firefly luciferase (Fluc) reporter were used to test the
influence of BDNF UTRs on efficiency of translation in stimulated
conditions. Around 3000 SK-N-BE cells per well were seeded in 96-well
plate designed for luminescence assays (BD Falcon, CA, USA) and induced
to differentiate, as described. Differentiated cells were co-transfected with
one of the above construct along with a vector containing a Renilla (Rluc)
reporter as transfection control. Transfection was stopped after 6 h by
replacing media or starting the 24 h-point cisplatin treatment with/without
aurora kinase inhibitor in SFM. The day after, a 6 h-point treatment was also
performed before carrying out the Dual-Luciferase® (E1910, Promega
Corporation) assay in an automated Glomax plate reader (Promega
Corporation), according to manufaturer’s instructions.
Cell-survival analysis
A colorimetric MTT assay was performed to assess cell survival. 5000
SK-N-BE cells were plated in 96-well plates, maintained, let to
differentiate, then treated as described in the ‘Real-Time PCR’ paragraph.
Viability was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, TOX1, Sigma-Aldrich) following
manufacturer’s instructions.
Immunofluorescence and microscopy
Immunofluorescence on SK-N-BE cells was performed as follows, after
fixation in 4% paraformaldehyde (PFA) in phosphate-buffer-saline (PBS)
for 20 min at room temperature, cells were washed with PBS and
permeabilized for 15 min with PBS-Triton X-100 0.1% (PBS-T), then
blocked with PBS-T and 2%BSA. Thereafter, cells were incubated for 2 h at
room temperature with primary antibodies diluted 1:50 in blocking solution.
After three washes in PBS, cells were incubated 1 h at room temperature
with secondary antibodies conjugated with Alexa Fluor 488 or 568
fluorophores, diluted 1:200 in PBS-T, then washed with PBS and stained
with Hoechst to label nuclei. Finally, coverslips were mounted in Mowiol
antifade compound (Sigma-Aldrich). The following antibodies were
employed: Mouse monoclonal anti-BDNF (B5050, Sigma-Aldrich);
Rabbit polyclonal anti-actin (A5060, Sigma-Aldrich); anti-mouse Alexa
Fluor 488 (A11001, Invitrogen); anti-rabbit Alexa Fluor 568 (A10042,
Invitrogen).
Images for cell counting were acquired using a Nikon Eclipse E800
epifluorescence microscope with a 20× objective and a Nikon DXM1200
camera. Cells were manually counted with a stereological unbiased
procedure and counted using the ‘optical dissector’ method (West, 2002;
Mariotti et al., 2002; Tongiorgi et al., 2003), obtained by superimposing a
100×100 µm grid onto 3 different fields of 674×539 µm randomly
positioned in each well of 24-wells plate. This grid generated about 30
fields, and according to the stereological principles, only 5 were used to
count cells starting by chance from a number from 1-30 and avoiding
counting cells in contact with the right and lower boundaries (Tongiorgi
et al., 2003; West, 2002). In total, 1/6 of the reference space was sampled.
The number of cells is expressed as relative percentage with respect to the
untreated condition set as=100% (average from n=3 cultures). Images for
BDNF expression analysis were acquired using a Nikon Eclipse C1si
confocal microscope system mounted on a Nikon TE-2000U inverted
microscope with a 60× objective; BDNF spots were counted using ImageJ
1.45b software (NIH, Bethesda, USA) and expressed over the cell area in
µm2. Briefly, images were processed for z-stack projections and thresholds
were applied to highlight spots and cells area and then analysed using the
Analyze Particle tool. All images from different treatment conditions were
processed using the same parameters.
Statistical analysis
For MTT assay, we performed a two-way ANOVA followed by Bonferroni
correction versus DMSO (control) group, using GraphPad Prism, Version
5.03 (GraphPad Software, Inc.), also to generate the graph. All other
statistical analysis and graphs were performed using SigmaPlot 11.0 (Systat
Software, Inc.). One-way ANOVAs followed by Holm-Sidak corrections
against control were performed to compare treated groups against controls.
For all analyses, the statistical significance was set at P<0.05.
Acknowledgements
Wewould like to thank Fabio Gasparri, from NervianoMedical Science, for providing
us the aurora kinases inhibitor reagent and for supporting C.A. internship.
Competing interests
The authors C.A., A.P., G.B., A.C. and E.T. declare no conflict of interest. P.C. is an
employee of Nerviano Medical Sciences, who developed the aurora kinases
inhibitor PHA-680632.
Author contributions
E.T., P.C. and G.B. conceived the experiments. A.P., C.A., G.B. and A.C. conducted
the experiments and analysed the results. A.P. and E.T. wrote the manuscript. G.B.,
A.C. and P.C. critically read the text. All authors reviewed the manuscript.
Funding
This work was supported by Ministero dell’Istruzione, dell’Universita ̀ e della Ricerca
Progetto di formazione [DM 38163 to C.A.]. This work was also funded by
[PRIN2010-11 2010N8PBAA] from Ministero dell’Istruzione, dell’Universita ̀ e della
Ricerca (In-BDNF network) and Fra-UniTs to E.T. G.B. fellowship is supported by
Fondazione Benefica Kathleen Foreman Casali and Beneficentia Stiftung-Vaduz
(Lichtenstein).
References
Aid, T., Kazantseva, A., Piirsoo, M., Palm, K. and Timmusk, T. (2007). Mouse
and rat BDNF gene structure and expression revisited. J. Neurosci. Res. 85,
525-535.
Baj, G. and Tongiorgi, E. (2009). BDNF splice variants from the second promoter
cluster support cell survival of differentiated neuroblastoma upon cytotoxic stress.
J. Cell Sci. 122, 36-43.
Baj, G., Leone, E., Chao, M. V. and Tongiorgi, E. (2011). Spatial segregation of
BDNF transcripts enables BDNF to differentially shape distinct dendritic
compartments. Proc. Natl. Acad. Sci. USA 108, 16813-16818.
Baj, G., Del Turco, D., Schlaudraff, J., Torelli, L., Deller, T. and Tongiorgi, E.
(2013). Regulation of the spatial code for BDNF mRNA isoforms in the rat
hippocampus following pilocarpine-treatment: a systematic analysis using laser
microdissection and quantitative real-time PCR. Hippocampus 23, 413-423.
Bassili, M., Birman, E., Schor, N. F. and Saragovi, H. U. (2010). Differential roles
of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex
vivo and in vivo. Cancer Chemother. Pharmacol. 65, 1047-1056.
Bottone, M. G., Soldani, C., Veneroni, P., Avella, D., Pisu, M. and Bernocchi, G.
(2008). Cell proliferation, apoptosis andmitochondrial damage in rat B50 neuronal
cells after cisplatin treatment. Cell Prolif. 41, 506-520.
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R.,
Light, J. E., Kolla, V. and Evans, A. E. (2009). Trk receptor expression and
inhibition in neuroblastomas. Clin. Cancer Res. 15, 3244-3250.
Buhagiar, A. and Ayers, D. (2015). Chemoresistance, cancer stem cells, and
miRNA influences: the case for neuroblastoma. Anal. Cell. Pathol. 2015,
150634.
Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C. and Perez, J. M.
(2007). Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents
Med. Chem. 7, 3-18.
Cunha, C., Brambilla, R. and Thomas, K. L. (2010). A simple role for BDNF in
learning and memory? Front. Mol. Neurosci. 3, 1.
Feng, X., Jiang, H., Baik, J. C., Edgar, C. and Eide, F. F. (2001). BDNF
dependence in neuroblastoma. J. Neurosci. Res. 64, 355-363.
Fu, J., Bian, M., Jiang, Q. and Zhang, C. (2007). Roles of Aurora kinases in mitosis
and tumorigenesis. Mol. Cancer Res. 5, 1-10.
Fuertes, M. A., Castilla, J., Alonso, C. and Pérez, J. M. (2003). Cisplatin
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